Captrust Financial Advisors Apellis Pharmaceuticals, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$35.07 - $59.21 $350 - $592	10 Added 12.2%	92 $4,000
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $8,652 - $13,205	-244 Reduced 74.85%	82 $4,000
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $8,822 - $14,108	-287 Reduced 46.82%	326 $15,000
Q3 2021 Nov 16, 2021	BUY	$31.4 - $69.84 $15,511 - $34,500	494 Added 415.13%	613 $20,000
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $3,681 - $5,841	90 Added 310.34%	119 $8,000
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $1,183 - $1,664	29 New	29 $1,000

302

112M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.19B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.